Wellgistics Health Inc Dossier
Qualitative Analysis
Business overview
Wellgistics Health, Inc. (NASDAQ: WGRX), formerly known as Danam Health, Inc., is a healthcare technology and pharmaceutical logistics holding company incorporated in Delaware and headquartered in Tampa, Florida. The company operates a vertically integrated micro-health ecosystem designed to simplify and optimize prescription drug fulfillment from manufacturers to patients. Its business portfolio is structured around three core pillars: wholesale distribution, retail community specialty pharmacy, and a proprietary technology division. Wellgistics conducts its operations through wholly owned subsidiaries Wood Sage, LLC (which owns Alliance Pharma Solutions and Community Specialty Pharmacy) and Wellgistics LLC. Its proprietary technology stack includes the EinsteinRx™ AI-driven pharmacy dispensing platform, HubRx AI™ for intelligent prescription routing, and the patented PharmacyChain™ blockchain-enabled smart contracts platform developed in partnership with DataVault AI. This integrated platform connects over 6,500 independent pharmacies and 200 pharmaceutical manufacturers nationwide.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A comprehensive strategic initiative to build Wellgistics into 'DelivMeds AI, Inc.' (ticker reserved: NASDAQ:MEDS). This involves expanding Datavault AI's PharmacyChain™ license to include Healthcare-as-a-Service (HaaS) IP, acquiring the QOLPOM biometric IP, and acquiring a controlling stake in Tollo Health, LLC.
Expected impact: Establishes a vertically integrated technology, pharmacy, and telemedicine ecosystem with an estimated combined asset value of $4 billion.
Integrating the proprietary pharmacy dispensing optimization AI platform EinsteinRx™ with the patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey and enable tokenized healthcare data management.
Expected impact: Reduces onboarding friction, speeds up implementation times, and allows the company to onboard up to 500 pharmacies per month into the formal Wellgistics Pharmacy Network by year-end 2026.
Expanding into the fast-growing GLP-1 weight loss and metabolic therapy segment by marketing and distributing proprietary medical foods and nutraceuticals, starting with Forzet™, designed to mitigate muscle loss associated with GLP-1 agonist therapies.
Expected impact: Drives high-margin revenue opportunities across the network of 6,500+ independent pharmacies and establishes direct-to-consumer patient relationships.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of the operator of the Peek Meds Marketplace to add trade, distribution, and pharmacy services, providing a comprehensive suite of solutions to reduce prescription costs and enhance real-time pricing transparency for consumers.
Financial impact: The proposed acquisition of WellCare Today was terminated on June 30, 2026, resulting in no direct financial integration or operational impact.
Strategic Partnerships
Formalized a definitive joint venture combining Wellgistics Hub and KareRx Hub technology and operations. Integrates Wellgistics' EinsteinRx™ and HubRx AI™ with KareRx's digital hub to streamline the prescription journey from intake to fulfillment.
Terms: Combined ecosystem provides potential reach to an estimated 200,000+ patient lives across pharmaceutical and provider networks, expected to drive monthly pharmacy sales.
Partnership to advance the 'Health Lives Here' consumer health app, connecting the platform directly to patients managing chronic pain, orthopedic injury, and muscle-loss side effects accompanying GLP-1 agonist use.
Terms: Provides national brand reach and marketing support for the launch of Tollo Health's proprietary nutraceutical products, starting with Forzet™.